Across TCGA pan-cancer cohorts, PMCH Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PMCH data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PMCH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PMCH expression acts as an unfavorable survival marker.

LIHC are the cancer types where PMCH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: PMCH tumor-vs-normal RNA expression · all PMCH data types